MGC Pharmaceuticals Ltd. announced to confirm that it is commencing its clinical tests on human volunteers to determine the efficacy of its dermatological skin care products for the relief of redness, dryness, flaky and oily indications for skin prone to acne, seborrhea and psoriasis. Once this is completed, the company plans to immediately commence commercial sales in third quarter. The company is starting 3-month clinical tests on human volunteers across its 3 CBD based dermatological skin care products at the largest Slovenian private dermatological institution in the country since 2003. The clinical tests monitoring and independent result analysis will be performed by Rok Devjak, MD PhD. The tests will investigate the efficacy of the dermatological products for the relief of indications of redness, dryness, flaky, oily and acne prone skin in human volunteers. A dermatological product range presents a significant commercial opportunity for the company. MGC Pharmaceuticals expects to commence sales of a dermatological skin care product range by third quarter of 2017, immediately following the completion of the 3-month clinical trial. A dermatological product range represents the company's second revenue stream, is due to commence in the third 2017 following successful completion of the clinical tests. This complements MGC Pharmaceuticals' MGC Derma cosmetics product range, which has already commenced generating revenue for the company.